Sarah Sammons

Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors

Li Zhu, Jessica L. Narloch, Sayali Onkar et al. · Journal for ImmunoTherapy of Cancer · 2019 · 122 citations · Full text

Breast Oncology, Immunology, Immunoediting +18

Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton et al. · Journal of Clinical Oncology · 2024 · 71 citations

Lba1001 Background, Breast Oncology, Oncology +13

Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial

Matthew P. Goetz, N.A. Bagegni, Gerald Batist et al. · Annals of Oncology · 2023 · 56 citations · Full text

Freedom From Local and Regional Failure of Contralateral Neck With Ipsilateral Neck Radiotherapy for Node-Positive Tonsil Cancer: Results of a Prospective Management Approach

Kyle E. Rusthoven, David Raben, Charles Schneider et al. · International Journal of Radiation Oncology*Biology*Physics · 2009 · 50 citations

Radiation Therapy, Regional Failure, Nasopharyngeal Cancer +8

The Dysregulated Pharmacology of Clinically Relevant <i>ESR1</i> Mutants is Normalized by Ligand-activated WT Receptor

Kaitlyn J. Andreano, Jennifer G. Baker, Sunghee Park et al. · Molecular Cancer Therapeutics · 2020 · 50 citations · Full text